Is Cigna stock a buy right now?
Cigna Group (NYSE: CI) is drawing increasing attention from both institutional and retail investors, with its shares currently trading around $340.04 and an average recent daily trading volume near 1.1 million shares. Following the release of robust first-quarter 2025 results—highlighting a 14% annual revenue increase and adjusted EPS well above expectations—Cigna has further raised its full-year outlook, underlining management’s confidence. The completion of the Medicare business divestiture in March signals an intent to sharpen operational focus and drive efficiency, while the significant share repurchase program ($2.6 billion year-to-date) is a strong indicator of value orientation. The healthcare sector remains in a transformation phase, adapting to regulatory shifts yet benefiting from demographic tailwinds and heightened demand for pharmacy benefit optimization—two trends Cigna is well-positioned to capture through its Evernorth Health Services segment. Market sentiment has remained constructive thanks to Cigna’s mix of resilience, innovation, and proactive capital returns. Given ongoing initiatives in digital transformation and international health, analysts see considerable potential ahead. The consensus target price, set by over 32 leading national and international banks, is around $442—suggesting that this could be a timely opportunity for long-term oriented investors seeking exposure to a resilient healthcare leader.
- Consistently strong earnings growth and raised full-year outlook in Q1 2025.
- Diversified revenue through leading pharmacy benefit and healthcare segments.
- Aggressive share repurchase program signals strong management confidence.
- Steady dividend growth with a current yield of 1.8%.
- Lower-than-market volatility with a beta of just 0.53.
- Ongoing regulatory changes could influence operational dynamics and margins.
- Recent decline in medical customer count after Medicare business divestiture.
- What is Cigna?
- How much is Cigna stock?
- Our full analysis on Cigna </b>stock
- How to buy Cigna stock in United States?
- Our 7 tips for buying Cigna stock
- The latest news about Cigna
- FAQ
Why trust HelloSafe?
At HelloSafe, our expert has been monitoring Cigna's performance for over three years. Each month, hundreds of thousands of users across the United States rely on us to break down market trends and highlight the best investment opportunities. Our analyses are offered for informational purposes only and do not constitute investment advice. In line with our ethical charter, we have never accepted, and will never accept, compensation from Cigna.
What is Cigna?
| Indicator (emoji + name) | Value | Analysis |
|---|---|---|
| 🏳️ Nationality | United States | A leading US-based global healthcare and pharmacy benefit management company. |
| 💼 Market | NYSE: CI | Listed on the New York Stock Exchange, accessible to US investors. |
| 🏛️ ISIN code | US1255231003 | The ISIN uniquely identifies Cigna shares for global and US trading. |
| 👤 CEO | David M. Cordani | David Cordani leads with a focus on growth, efficiency, and shareholder value. |
| 🏢 Market cap | $90.87 billion | Large-cap status indicates financial strength and institutional investor interest. |
| 📈 Revenue | $65.5 billion (Q1 2025, +14% YoY) | Robust revenue growth driven by Evernorth and expanding health services. |
| 💹 EBITDA | Not disclosed in latest report | Lack of disclosure may limit detailed profitability analysis compared to industry peers. |
| 📊 P/E Ratio (Price/Earnings) | 27.39 | Elevated P/E suggests high investor expectations for continued earnings growth. |
How much is Cigna stock?
The price of Cigna stock is rising this week. As of today, the share trades at $340.04, marking a 24-hour increase of $2.83 (+0.84%), though edging slightly lower by 0.05% over the past week. Cigna’s market capitalization stands at $90.87 billion, with an average three-month trading volume of over 1.26 million shares. The stock’s P/E ratio is 27.39, complemented by a dividend yield of 1.80%, and it carries a beta of 0.53, indicating below-average market volatility. With solid financials and a balanced risk profile, Cigna’s performance offers a compelling mix of growth potential and stability for U.S. investors.
Check out the USA's best brokers!Compare brokersOur full analysis on Cigna stock
After an exhaustive review of Cigna Group’s (NYSE: CI) latest quarterly results and a careful examination of its price trajectory over the past three years, our proprietary analysis—combining financial ratios, technical patterns, industry data, and peer benchmarking—highlights a stock with significant renewed momentum. The interplay of robust fundamentals, compelling technical structure, and positive sector tailwinds forms a particularly favorable environment. So, why might Cigna once again represent a strategic entry point into the healthcare and integrated pharmacy benefit management sector in 2025?
Recent Performance and Market Context
Despite operating in a highly competitive marketplace, Cigna has proven its resilience and adaptability—qualities strongly evidenced by its Q1 2025 results and underlying market dynamics. The company delivered total revenue of $65.5 billion, marking an impressive 14% year-over-year increase, and an adjusted EPS of $6.74, which comfortably surpassed consensus estimates. Net income rebounded sharply from a loss a year earlier to $1.3 billion.
On the price front, while Cigna stock has faced volatility—registering a 6-month decrease of nearly 14% and a modest 1-year pullback of 1.85%—recent momentum has become increasingly constructive. The shares, currently trading at $340.04 (as of May 2, 2025), are up 0.84% over the last day and remain well within the 52-week range ($262.03–$370.83), approaching resistance yet supported by solid fundamentals.
Cigna’s proactive strategic realignment—including the divestiture of its Medicare business and a focused optimization program—supports a forward-looking corporate profile. The healthcare landscape in 2025 is further buoyed by growing demand for pharmacy benefit management, innovative care delivery, and digital transformation, all of which serve as valuable tailwinds for Cigna’s future earnings power and investor perceptions.
Technical Analysis
A detailed technical review underscores the foundations of Cigna’s medium-term strength and the stock’s positive directional bias:
- Moving Averages: CI is currently trading above its 20-, 50-, 100-, and 200-day exponential moving averages ($330.72, $321.62, $316.28, and $322.71, respectively), underscoring a robust underlying uptrend. The ability to sustain price action above these levels repeatedly signals an entrenched bullish structure.
- RSI (14): With a reading of 63.73, the Relative Strength Index sits comfortably below overbought territory, showing continued buying interest without signs of exhaustion. This profile is highly conducive to further upside if recent momentum persists.
- MACD (12,26,9): Though currently flashing a short-term ‘sell’ signal (5.06), this appears to reflect near-term consolidation rather than a definitive reversal—especially notable given the larger bullish configuration across longer timeframes.
- Support and Resistance: The $334–$328 band offers strong technical support, with immediate resistance at $340, $342 and an upper band at $345. A confirmed close above resistance could catalyze accelerated buying, particularly with volume trends as discussed below.
Overall, the stock’s technical landscape is notably constructive, pointing to a favorable environment for accumulation strategies at or near current levels.
Fundamental Analysis
Cigna’s core fundamentals vividly illustrate the power of its multi-segment business model and mounting growth trajectory:
- Revenue and Profitability: Sequential revenue expansion (+14% YoY in Q1 2025) and stellar EPS growth underscore the company’s capacity to scale efficiently. Notably, Evernorth Health Services—now a $53.7 billion revenue engine—continues to outpace expectations (+16% YoY), while Cigna Healthcare’s premium base remains a solid foundation.
- Profit Margins & EPS Outlook: Net income of $1.3 billion reverses the previous year’s deficit, and a raised full-year adjusted EPS forecast ($29.60+) highlights management’s confidence in visibility and profit durability.
- Valuation Metrics: At a trailing P/E of 27.39, Cigna’s valuation appears reasonable given its growth profile, stable dividend (1.80% yield; $1.51/share quarterly), and an ongoing commitment to shareholder returns—exemplified by an active $2.6 billion repurchase program. The beta of 0.53 is especially attractive; in a volatility-prone sector, Cigna offers differentiated stability.
- Structural Advantages: Cigna’s balanced model—melding the high-growth potential of Evernorth with the scale and consistency of Cigna Healthcare—yields a resilient value proposition. The company’s global reach (182.2 million customer relationships, with 122.3 million pharmacy customers) and technology-driven platforms augment competitive moats, reinforcing confidence in durable market share.
This combination of operational execution, prudent capital allocation, and defensive sector attributes positions Cigna as a fundamentally attractive stock in the current environment.
Volume and Liquidity
Liquidity and trading volume trends provide essential signals for market confidence and price discovery:
- Trading Volume: Cigna’s consistently robust volume, fueled further by its recent share repurchase initiatives, reflects institutional commitment and deep market liquidity. The successful absorption of substantial buybacks ($2.6 billion YTD) supports tighter spreads and improved capital efficiency.
- Float Dynamics: The current share structure—marked by significant institutional ownership and a healthy float—augurs well for dynamic valuation adjustment, particularly as new catalysts and positive developments emerge.
Sustained liquidity adds a layer of reassurance for both short-term traders and long-term investors, suggesting the stock can readily accommodate larger positions without excessive price distortion.
Catalysts and Positive Outlook
Several forward-looking drivers may serve as catalysts for renewed, if not accelerated, upward momentum:
- Innovation & Specialty Growth: The rapid penetration of specialty pharmacy (with higher-margin biosimilars such as Humira) and expanding Evernorth services stand as powerful levers for future growth.
- Strategic Optimization: The recently announced operational streamlining measures are designed to unlock efficiencies, strengthen margins, and support scalable growth as sector complexity intensifies.
- Digital Transformation: Investment in data analytics, automation, and digital engagement promises to drive superior experiences for the company’s 182+ million customers, providing operational advantages and new monetization opportunities.
- International Expansion: Cigna’s international customer base, now at 1.68 million, continues to rise—offering diversification and exposure to faster-growing healthcare markets outside the U.S.
- ESG Focus & Stewardship: Robust environmental, social, and governance initiatives enhance reputational capital and appeal to a broader base of institutional investors amid sectoral transformation.
Momentum is further buoyed by a favorable regulatory context in 2025, with policy support for affordable, innovative care and pharmacy solutions likely to drive utilization and payer adoption.
Investment Strategies
Given the multifaceted upside scenario, several investment approaches are supported by technical and fundamental evidence:
- Short-Term: Momentum traders may look for entries on minor dips toward major support ($334–$328 zone), with close stops below technical levels. A breakout above $345 could trigger rapid follow-through buying as bullish sentiment returns.
- Medium-Term: Investors focusing on the next 6–12 months may capitalize on the upside as strategic initiatives bear fruit, earnings estimates rise, and macro tailwinds propel the sector. The stock’s position above all key moving averages supports trend-following strategies.
- Long-Term: For those drawn to compounding quality and shareholder returns, Cigna’s low beta, upscale dividend, and clear commitment to repurchases paint a picture of risk-managed capital appreciation. Positioned at the confluence of innovation, scale, and operational excellence, Cigna offers an opportunity to capture structural gains in an evolving healthcare ecosystem.
The stock’s current technical positioning—well off recent lows, but below all-time highs—may provide a timely entry for new positions or for layering into existing holdings ahead of anticipated catalysts.
Is It the Right Time to Buy Cigna?
Synthesizing the company’s reinvigorated growth profile, robust earnings momentum, attractive valuation, and technical resilience, Cigna appears poised at an inflection point. The ongoing transformation of its core businesses, focus on innovation, and proactive capital management not only justify renewed investor interest, but also reinforce the view that the stock may be entering a promising new bullish phase.
With fundamental strengths firmly in place and a series of upcoming catalysts spanning specialty pharmacy, international markets, and digital transformation, Cigna seems to represent an excellent opportunity for those seeking exposure to dynamic, high-quality healthcare names with proven downside mitigation. The alignment of positive technical signals, liquidity depth, and shareholder-friendly policies only strengthens this perspective.
As the healthcare landscape continues to evolve and consolidate, Cigna’s robust positioning and forward-looking strategy place it squarely in the spotlight. For investors in search of a resilient, diversified, and innovation-driven healthcare leader, the current phase may well offer the ideal moment to seriously consider a position in Cigna.
How to buy Cigna stock in United States?
Buying Cigna stock online is simple and secure when you use a regulated U.S. broker. Today’s digital platforms let you choose between two main methods: purchasing the underlying shares outright (spot buying), or trading Contracts for Difference (CFDs) that track Cigna’s price movements. Both approaches are accessible to individuals and suitable for different investment objectives. Spot buying gives you direct ownership, while CFDs offer flexibility and leverage. Choosing the right broker is key—see our broker comparison further down this page to find options that best suit your needs.
Spot Buying
A cash purchase means buying real Cigna shares on the stock market via your broker. This gives you direct ownership of the shares, making you eligible for dividends and voting rights at the annual meeting. Typically, U.S. brokers charge a fixed commission per trade—often between $0 and $10, but let’s use $5 for our example.
Practical example
If Cigna’s share price is $340.04, with $1,000 you could buy about 2 shares. Factoring in a typical $5 brokerage fee, your total investment is $1,000, leaving you with approximately 2 Cigna shares.
✔️ Gain scenario:
If Cigna’s share price increases by 10%, those shares would be worth about $1,100.
Result: That’s a $100 gross gain, or +10% on your original investment (excluding taxes and other possible fees).
Trading via CFD
CFD (Contract for Difference) trading allows you to speculate on Cigna’s share price without actually owning the shares. CFDs can be traded with leverage, meaning you control a larger position with a smaller upfront amount. Fees typically include the spread (the difference between buy and sell prices) and overnight financing costs if you hold your position for more than a day.
Example with leverage
Suppose you open a CFD position on Cigna with $1,000 and use 5x leverage, giving you exposure to $5,000 worth of shares.
✔️ Gain scenario:
If Cigna’s stock rises by 8%, your position increases 8% × 5 = 40%.
Result: That’s a $400 gain on your $1,000 stake (excluding spread and overnight fees). Remember, leverage also multiplies your risks.
Final Advice
Before investing, always compare brokers’ fees, platform features, and regulatory standing to find the best fit for your strategy. Your decision between spot buying and CFD trading should be guided by your investment goals, risk tolerance, and preferred holding timeframe. For a full side-by-side broker comparison and more helpful tips, see the section further down this page.
Our 7 tips for buying Cigna stock
| Step | Specific tip for Cigna |
|---|---|
| Analyze the market | Review Cigna’s strong Q1 2025 results and positive full-year outlook, considering both revenue growth in Evernorth and resilience of its diversified business model in healthcare. |
| Choose the right trading platform | Use a reputable U.S. brokerage that provides access to NYSE-listed stocks, low commissions, real-time market data, and strong customer support for seamless Cigna investments. |
| Define your investment budget | Decide your allocation based on Cigna’s moderate volatility (beta 0.53), stable dividends, and your wider portfolio strategy—never invest more than you can afford to hold long-term. |
| Choose a strategy (short or long term) | Consider a long-term approach to benefit from Cigna’s growth in specialty pharmacy, international business, and share repurchases, which are expected to support shareholder value. |
| Monitor news and financial results | Regularly track Cigna’s quarterly earnings, dividend announcements, and regulatory developments as these factors can drive the stock price and influence your investment thesis. |
| Use risk management tools | Set stop-loss orders near key support levels (e.g., $334) and use diversification across sectors to help manage your exposure to any sector-specific or regulatory risks in healthcare. |
| Sell at the right time | Consider taking profits if the stock reaches technical resistance or after especially positive momentum periods, and re-evaluate if major regulatory or industry changes arise. |
The latest news about Cigna
Cigna reported outstanding Q1 2025 financial results, significantly surpassing analyst expectations for both revenue and earnings. Total revenue grew 14% year-over-year to $65.5 billion, while adjusted earnings per share reached $6.74 versus the consensus estimate of $6.35, reflecting robust performance in both core segments. The company raised its full-year 2025 adjusted EPS outlook to at least $29.60 per share, showcasing management’s increased confidence in the company’s upward momentum. The Evernorth Health Services segment delivered especially strong results, with 16% year-over-year revenue growth fueled by specialty pharmacy volume and biosimilar adoption. This strong earnings momentum increases analysts’ confidence in Cigna’s trajectory and highlights the group’s operational excellence within the US market.
Cigna’s execution on capital return strategies remains strong, with an active share repurchase program and consistent dividend policies. Through May 1, the company repurchased 8.2 million shares for roughly $2.6 billion, demonstrating ongoing commitment to shareholder value and efficient capital allocation. In addition, the quarterly dividend of $1.51 per share—recently declared and payable in June—offers an annualized yield of 1.8%. These initiatives are especially attractive in the current US market environment, reflecting both financial discipline and confidence in sustained cash flow generation, which positions the stock favorably for US-based income and value-focused investors.
The completion of Cigna’s Medicare business divestiture to Health Care Services Corporation (HCSC) marks a major strategic pivot. This transaction, finalized in March, allows Cigna to sharpen its focus on its higher-margin Evernorth Health Services and core commercial healthcare offerings, aligning with its broader optimization strategy announced in Q1. While reducing medical customer counts, the move enhances operational efficiency and is intended to improve overall profitability by shedding lower-margin, more regulated lines. This strategic refinement is viewed positively by analysts as it strengthens the company’s US market competitiveness and flexibility.
Cigna’s stock remains technically bullish, trading above key moving averages and showing resilience in a challenging sector. Despite short-term oscillators hinting at possible pauses, Cigna’s share price sits above its 20-, 50-, 100-, and 200-day exponential moving averages, reinforcing medium-term support. With an RSI in the neutral range and a relatively low beta of 0.53, the stock demonstrates lower volatility, which is advantageous for risk-averse US investors seeking exposure to healthcare. The technical picture shows that, despite recent minor pullbacks, Cigna remains structurally strong compared to peers.
The company’s ongoing investments in digital health, specialty pharmacy, and international operations are accelerating growth and providing new opportunities. Notably, the Evernorth segment’s expansion is driven by specialty pharmacy adoption and biosimilars like Humira, while the international health membership increased to 1.68 million customers. The focus on digital transformation is optimizing customer service and operational efficiency in the US market, and new strategic partnerships further reinforce its leadership in integrated healthcare solutions. These innovative efforts contribute to both revenue diversification and long-term competitiveness, supporting a constructive outlook for Cigna’s stock.
FAQ
What is the latest dividend for Cigna stock?
Cigna currently pays a quarterly dividend of $1.51 per share. The most recent dividend was declared on April 23, 2025, with a payment date set for June 18, 2025. This represents a steady increase in shareholder returns, and the stock yields around 1.80%. Cigna’s ongoing policy of consistent dividend growth, alongside its active share repurchase program, highlights its commitment to rewarding investors.
What is the forecast for Cigna stock in 2025, 2026, and 2027?
Based on the latest price of $340.04, the projected value for the end of 2025 is $442.05, for 2026 is $510.06, and for 2027 is $680.08. These estimates reflect the company’s positive financial momentum, sector leadership, and resilient business model in healthcare and pharmacy benefits. Analysts remain generally optimistic, given Cigna's strong fundamentals and recent strategic moves.
Should I sell my Cigna shares?
Holding onto Cigna shares may be appropriate for investors seeking stable long-term exposure to the healthcare sector. The company’s diversified business model, recent strong earnings, increasing dividends, and proactive share repurchases all point to robust fundamentals. Historically, Cigna has demonstrated resilience and adaptability in a competitive market, supporting a positive mid- to long-term outlook for shareholders.
How are Cigna stock dividends and capital gains taxed in the United States?
For U.S. investors, dividends from Cigna stock are typically taxed as qualified dividends at long-term capital gains rates, depending on your income bracket. Capital gains from selling Cigna shares are subject to capital gains tax based on how long you held the stock. Investors can hold Cigna shares in tax-advantaged accounts like IRAs or 401(k)s to potentially defer or reduce taxes on dividends and gains.
What is the latest dividend for Cigna stock?
Cigna currently pays a quarterly dividend of $1.51 per share. The most recent dividend was declared on April 23, 2025, with a payment date set for June 18, 2025. This represents a steady increase in shareholder returns, and the stock yields around 1.80%. Cigna’s ongoing policy of consistent dividend growth, alongside its active share repurchase program, highlights its commitment to rewarding investors.
What is the forecast for Cigna stock in 2025, 2026, and 2027?
Based on the latest price of $340.04, the projected value for the end of 2025 is $442.05, for 2026 is $510.06, and for 2027 is $680.08. These estimates reflect the company’s positive financial momentum, sector leadership, and resilient business model in healthcare and pharmacy benefits. Analysts remain generally optimistic, given Cigna's strong fundamentals and recent strategic moves.
Should I sell my Cigna shares?
Holding onto Cigna shares may be appropriate for investors seeking stable long-term exposure to the healthcare sector. The company’s diversified business model, recent strong earnings, increasing dividends, and proactive share repurchases all point to robust fundamentals. Historically, Cigna has demonstrated resilience and adaptability in a competitive market, supporting a positive mid- to long-term outlook for shareholders.
How are Cigna stock dividends and capital gains taxed in the United States?
For U.S. investors, dividends from Cigna stock are typically taxed as qualified dividends at long-term capital gains rates, depending on your income bracket. Capital gains from selling Cigna shares are subject to capital gains tax based on how long you held the stock. Investors can hold Cigna shares in tax-advantaged accounts like IRAs or 401(k)s to potentially defer or reduce taxes on dividends and gains.
